---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027472"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T17:51:39.355465+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion Q3 2022 product rev $14.0M (+28% Y/Y); net loss $55.1M; CLEAR Outcomes trial finished

## Summary
- U.S. net product revenue $14.0M (up 28% YoY); total revenue $19.0M (up 32% YoY).
- Net loss $55.1M ($0.81 diluted EPS) vs $69.4M loss ($2.62 EPS) in Q3 2021.
- CLEAR Outcomes trial achieved last patient last visit in Oct 2022; topline results expected Jan 2023.
- SG&A down 36% YoY to $25.0M; R&D up 15% to $29.1M; cash $239.3M (down $70M from Dec 2021).
- Reaffirmed FY2022 OpEx guidance: total $220-240M including $25M stock-based comp.

## SEC filing metadata
- accession: 0001628280-22-027472
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/0001628280-22-027472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/espr-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027472
- JSON: https://secwatch.observer/filing/0001628280-22-027472.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027472.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $19.0 million, net income net losses of $55.1 million, EPS $0.81. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $19.0 million
  - Net income: net losses of $55.1 million
  - EPS: $0.81
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the third quarter ended September 30, 2022, was $19.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/0001628280-22-027472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.